A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

Mark Hertzberg, Jane Matthews, Janey Stone, Ming-Celine Dubosq, Andrew Grigg, David Ellis, Warwick Benson, Peter Browett, Noemi Horvath, Henry Januszewicz, Ehtesham Abdi, Michael Green, Tony Bonaventura, Paula Marlton, Paul Cannell, Max Wolf

    Research output: Contribution to journal › Article › peer-review

    8 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science

    Agricultural and Biological Sciences